Retrospective review of daratumumab/bortezomib/dexamethasone (DVd) with weekly administration of bortezomib M Abousaud, J Duda, L Kennedy, E Dressler, C Rodriguez Wake Forest University Baptist Medical Center - PGY1 - Winston-Salem, NC
Background/Purpose: Based on the CASTOR trial, the combination of daratumumab, twice weekly subcutaneous (SC) bortezomib, and dexamethasone was given a category 1 designation for patients with relapsed and/or refractory multiple myeloma (MM). A common, notable non-hematologic adverse effect that leads to dose modification or discontinuation of bortezomib is peripheral sensory neuropathy. At Wake Forest Baptist Health (WFBH), patients with MM are treated with weekly SC bortezomib and daratumumab plus dexamethasone in order to reduce rates of peripheral neuropathy. The purpose of this study is to evaluate response rates, progression free survival rates (PFS), and incidence of neuropathy of weekly SC bortezomib, daratumumab, and dexamethasone.
Methodology: An observational, single-center, non-randomized, retrospective chart review was conducted between December 1, 2015 to July 1, 2018. Patients were included if they were 18 years of age or older with MM who received weekly DVd, if they received all of their chemotherapy doses at a WFBH Hematology/Oncology infusion clinic, and if they received at least 2 doses of weekly DVd within 7 days of each dose. Patients were excluded if they received twice weekly SC bortezomib or intravenous (IV) bortezomib either weekly or twice weekly. The primary objective is to evaluate response rates among MM patients on weekly DVd. The secondary objectives are to evaluate PFS rates, rates and severity of peripheral neuropathy.
Presentation Objective: Assess the potential risks and benefits of weekly versus twice weekly SC bortezomib administration
Self-Assessment: What is one of the benefits of weekly SC bortezomib in comparison to twice weekly SC bortezomib in the DVd regimen?
